https://retractionwatch.com/2022/10/07/paper-by-gene-therapy-zolgensma-developer-retracted-because-of-discrepancies-in-mouse-survival-rates/
Bryan Kaspar A paper describing preclinical work on what appears to be the gene therapy for spinal muscular atrophy now sold as Zolgensma has been retracted for data inaccuracies.  The article…
Create an account or login to join the discussion